[1] |
XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue.
285 cases of adverse drug reaction related to new antineoplastic drugs
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
|
[2] |
ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie.
Adverse reaction monitoring of toothpaste in China under the new regulatory system
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222.
|
[3] |
GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe.
Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5.
|
[4] |
TAI Jun, YU Miao, ZHANG Lin, LEI Yi, LIU Junting, LI Tao, HUANG Guimin, CHENG Yijing, NIE Xiaolu, WANG Qing.
Active monitoring of adverse reactions related to haemocoagulase agkistrodon for injection in children
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1011-1016.
|
[5] |
LI Xingren, SHEN Aizong, SU Dan.
Evaluation of the rationality of proton pump inhibitors in preventing perioperative stress related mucosal disease in biliary and pancreatic surgery
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1022-1026.
|
[6] |
ZHANG Li, WANG Yujia, ZHANG Lingling, CHEN Jiaxin, LIN Minhua, LIN Xiaohui, NIE Xuekun.
Surveillance data on adverse reactions associated with real-world immune checkpoint inhibitors
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1035-1038.
|
[7] |
YU Hongli, YU Dongmei, XIAO Aili, ZHU Lan, SONG Haibo.
Risks of safety Qingkailing oral preparation
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1046-1048.
|
[8] |
ZOU Dongmei, FANG Fang, GUO Yixian, NI Jing, ZHAO Hong, HU Ronghua, SUN Wanling.
Analysis of the association of adverse reactions with relative dose of melphalan and body weight in POEMS syndrome patients undergoing melphalan-based ASCT
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 911-914.
|
[9] |
YANG Le, XIA Dongsheng, WANG Tao.
Risks to safety of vitamin B6 injection
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 791-794.
|
[10] |
HUANG Cuili, GAO Ao, WANG Jiaxi, GUO Haili, XU Xiaohan, CHENG Yinchu, GUO Daihong.
Automatic monitoring and assessment of antibiotics-related thrombocytopenia
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 807-811.
|
[11] |
LIU Yuanxi, GU Donglin, WANG Qi, YAO Lingwen, WANG Ying, JIN Hongyu, MA Shuangcheng.
Determination of 87 types of pesticide residues in Polygoni Multiflori Radix by LC-MS/MS
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 601-608.
|
[12] |
ZHAO Yan, LIU Wenbo, ZHAO Yifei, LI Dong, ZHENG Lijia, SONG Yana, ZHAO Yujuan, DONG Fang.
Applicability of patient registry research to regulation of medical devices
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 423-427.
|
[13] |
ZHENG Yujing, ZHAO Zinan, JIN Pengfei, ZHAO Fei, HU Xin, ZHANG Yatong.
Active monitoring of adverse reactions of capecitabine-induced hand-foot syndrome based on the hospital information system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 441-443.
|
[14] |
JIAO Fuzhi, CHEN Yarui, JI Wei, HAO Jianpeng, GUAN Quanlin.
Short-term efficacy and safety evaluation of PD-1 inhibitor combined with chemotherapy as a first-line neoadjuvant therapy for locally advanced gastric adenocarcinoma
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 301-305.
|
[15] |
WANG Jiaxi, GUO Daihong, ZHANG Bo, Li Boyan, GUO Haili.
Automatic monitoring and risk factors of acute kidney injury in 116097 dosing cases of flurbiprofen axetil
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 201-205.
|